ACADIA Pharmaceuticals Inc

ACAD

Healthcare|Biotechnology|USA

$26.22

-0.19 (-0.72%)

DCF (FCF)

$4.73

Tangible Book

$6.67

Graham Number

$18.18

Earnings Power

$5.25

About

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.

Stock Price

+18.9%(1Y)

Pipeline Summary

54 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 27Terminated: 9ENROLLING_BY_INVITATION: 3Withdrawn: 3Active: 1Recruiting: 7APPROVED_FOR_MARKETING: 1Unknown: 2NOT_YET_RECRUITING: 1

Active Trials (8)

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06173531Hyperphagia in Prader-Willi Syndrome

Phase 3Active

Enrollment: 170 participants

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

NCT05999240Autism Spectrum Disorder

Phase 2Recruiting

Enrollment: 30 participants

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673Alzheimer's Disease Psychosis

Phase 2Phase 3Recruiting

Enrollment: 1,074 participants

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT07284667Major Depressive Disorder (MDD)

Phase 2Recruiting

Enrollment: 153 participants

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

NCT07029581Lewy Body Dementia Psychosis

Phase 2Recruiting

Enrollment: 180 participants

View all 8 active trials →

BioScore

5.4/10

Watchlist

Ownership

Recent Insider Trades

Kihara JamesSELL

2026-06-2611,421 shares @ $26.08

Kihara JamesSELL

2026-05-265,401 shares @ $21.18

Kihara JamesSELL

2026-05-041,332 shares @ $21.79

Schneyer Mark C.SELL

2026-05-043,506 shares @ $21.79

Schneyer Mark C.SELL

2026-04-072,709 shares @ $22.2

Recent News

2026-07-07 16:03:39

2026-07-06 15:28:35

2026-07-06 14:00:12

2026-06-30 18:02:07

2026-06-30 00:00:19

Data last updated: Jul 12, 2026, 07:37 PM